← SynDRA
LIDOFLAZINE
SynDRA canonical compound SYN0003702 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Primary target(s) | SCN1A | SCN3A | SLC29A1 |
| Mechanism of action | calcium channel blocker |
| Indication | coronary artery disease (CAD) |
| Disease area | cardiology |
All known targets
- SLC29A1
- SCN3A
- KCNH2
- SCN1A
- Scn1a
- Scn2a
- Scn3a
Mechanisms of action (all sources)
- calcium channel blocker
- SCN3A INHIBITOR
- SLC29A1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SLC6A3
- DRD3
- HRH1
- ADRA1A
- ADRA2A
- ADRA2B
- ADRA2C
- HTR2A
- HTR2B
- SLC6A4
- OPRK1
- SLC6A2
- DRD1
- DRD2
- MC3R
- LMNA
- ADORA1
- KDM4A
- IDH1
- HTR3A
- NPY1R
- HTR2C
- MLNR
- OPRM1
- NR1I2
- NR3C1
- OPRD1
- HRH3
- PDE3A
- PDE4D
- PGR
- PTGS2
- PTH1R
- SAMHD1
- SMAD3
- TBXA2R
- TDP1
- USP1
- HTR1A
- GMNN
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- 5HT2A
- ANDR
- RARA
- NSD2
- MDR1
- MDM4
- MDM2
- KSYK
- IL1B
- ESRRA
- CP3A7
- CP2D6
- CP2CJ
- CP2C9
- BRCA1
- BARD1
- APAF
- SYK
Drug classes
- Calcium Channel Blockers
- Calcium-Regulating Hormones and Agents
- Cardiovascular Agents
- Membrane Transport Modulators
- Vasodilator Agents
ATC classes
- C08E · NON-SELECTIVE CALCIUM CHANNEL BLOCKERS
Cross-references
Synonyms
- corflazine
- lidoflazin
- lidoflazinum
- ordiflazine
- Lidoflazina
- MCN-JR-7904
- R-7904
- Angex
- Clinium
- Ordiflazine
- Corflazine
- Lidoflazinum
- Lidoflazin
- Klinium
- Lidoflazina [Italian]
- UNII-J4ZHN3HBTE
- Lidoflazinum [INN-Latin]
- Lidoflazina [INN-Spanish]
- Lidoflazine [USAN:INN:BAN]
- C30H35F2N3O
- J4ZHN3HBTE
- EINECS 222-312-8
- R 7904
- BRN 0904339
- CHEMBL92870
- 4-(4,4-Bis(p-fluorophenyl)butyl)-1-piperazineaceto-2',6'-xylidide
- 1-Piperazineacetamide, 4-(4,4-bis(4-fluorophenyl)butyl)-N-(2,6-dimethylphenyl)-
- NCGC00016627-01
- NCGC00016627-04
- CAS-3416-26-0
- McN-JR 7904
- DTXCID4025377
- RefChem:389096
- C08EX01
- Lidoflazine.5%
- Prestwick_700
- Angex (TN)
Look up LIDOFLAZINE in the interactive SynDRA portal →